Werewolf Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Longwood Fund III GP, LLC and Longwood Fund III, L.P. have updated their beneficial ownership in Werewolf Therapeutics, Inc. to 3.5% as of December 31, 2025.
NASDAQ
PFM Health Sciences and its affiliates have filed an amendment to their Schedule 13G, reporting a 0.9% beneficial ownership stake in Werewolf Therapeutics, Inc.
NASDAQ
PFM Health Sciences, LP and its affiliates have filed an amended Schedule 13G, revealing a continued beneficial ownership of 6.5% in Werewolf Therapeutics, Inc. as of December 31, 2024.